Article info

Download PDFPDF
Original article
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

Authors

  1. Correspondence to Dr Anthony Dohan, Radiology A, Hopital Cochin, Paris 75679, France; anthony.dohan{at}aphp.fr
View Full Text

Citation

Dohan A, Gallix B, Guiu B for the PRODIGE 9 Investigators and PRODIGE 20 Investigators, et al
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

Publication history

  • Received March 13, 2018
  • Revised April 28, 2019
  • Accepted April 30, 2019
  • First published May 17, 2019.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.